Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Adam Yuh Lin*, Joseph Michael Schnitter, Leo I. Gordon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system. Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma. The two most commonly used checkpoint inhibitors are pembrolizumab and nivolumab, both FDA approved as third-line therapy. There is increasing interest in the use of checkpoint inhibitors with combination chemotherapy or with other targeted agents in the second-line or even frontline setting. In this review, we will highlight the clinical trials that led to approvals of checkpoint inhibitors for Hodgkin lymphoma.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalImmunoTargets and Therapy
StatePublished - 2022


  • Checkpoint inhibitor
  • Hodgkin lymphoma
  • Nivolumab
  • Pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this